## Nanne K De Boer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1608735/publications.pdf

Version: 2024-02-01

180 papers

4,446 citations

35 h-index 149698 56 g-index

181 all docs

181 docs citations

181 times ranked

4468 citing authors

#	Article	IF	CITATIONS
1	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 785-792.	8.1	196
2	Azathioprine Use During Pregnancy: Unexpected Intrauterine Exposure to Metabolites. American Journal of Gastroenterology, 2006, 101, 1390-1392.	0.4	148
3	Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut, 2014, 63, 451-457.	12.1	128
4	Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 33-45.	1.3	124
5	Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study. International Journal of Cancer, 2014, 134, 1132-1138.	5.1	123
6	Systematic review with metaâ€analysis: SARSâ€CoVâ€2 stool testing and the potential for faecalâ€oral transmission. Alimentary Pharmacology and Therapeutics, 2020, 52, 1276-1288.	3.7	113
7	Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 686-694.	1.7	107
8	Dose-Dependent Influence of 5-Aminosalicylates on Thiopurine Metabolism. American Journal of Gastroenterology, 2007, 102, 2747-2753.	0.4	95
9	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to antiâ€₹NF treatment. Alimentary Pharmacology and Therapeutics, 2020, 52, 123-134.	3.7	92
10	Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 363-369.	1.9	89
11	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	1.3	85
12	Histopathology of liver biopsies from a thiopurine-na $\tilde{A}^-$ ve inflammatory bowel disease cohort: Prevalence of nodular regenerative hyperplasia. Scandinavian Journal of Gastroenterology, 2008, 43, 604-608.	1.5	75
13	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut, 2011, 60, 456-462.	12.1	72
14	Early Detection of Necrotizing Enterocolitis by Fecal Volatile Organic Compounds Analysis. Journal of Pediatrics, 2015, 167, 562-567.e1.	1.8	72
15	Long-Term Follow-Up of Transgender Women After Secondary Intestinal Vaginoplasty. Journal of Sexual Medicine, 2016, 13, 702-710.	0.6	68
16	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis, 2018, 12, 610-620.	1.3	67
17	Risk Factors for Necrotizing Enterocolitis: A Prospective Multicenter Case-Control Study. Neonatology, 2018, 114, 277-284.	2.0	66
18	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Alimentary Pharmacology and Therapeutics, 2020, 51, 880-888.	3.7	64

#	Article	IF	Citations
19	Risk Factors for Late-Onset Sepsis in Preterm Infants: A Multicenter Case-Control Study. Neonatology, 2019, 116, 42-51.	2.0	60
20	Necrotizing Enterocolitis, Gut Microbiota, and Brain Development: Role of the Brain-Gut Axis. Neonatology, 2019, 115, 423-431.	2.0	59
21	Finding hidden treasures in old drugs: the challenges and importance of licensing generics. Drug Discovery Today, 2018, 23, 17-21.	6.4	57
22	Necrotizing Enterocolitis. Inflammatory Bowel Diseases, 2015, 21, 436-444.	1.9	55
23	Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World Journal of Gastroenterology, 2016, 22, 9012.	3.3	53
24	The Scent of Colorectal Cancer: Detection by Volatile Organic Compound Analysis. Clinical Gastroenterology and Hepatology, 2014, 12, 1085-1089.	4.4	52
25	Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. PLoS ONE, 2015, 10, e0120299.	2.5	49
26	Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. Clinical Gastroenterology and Hepatology, 2017, 15, 1232-1241.e1.	4.4	47
27	Diversion neovaginitis after sigmoid vaginoplasty: endoscopic and clinical characteristics. Fertility and Sterility, 2016, 105, 834-839.e1.	1.0	45
28	On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance. Current Drug Metabolism, 2009, 10, 981-997.	1.2	43
29	Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. European Journal of Gastroenterology and Hepatology, 2005, 17, 457-461.	1.6	42
30	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2016, 55, 257-274.	3.5	42
31	Nodular regenerative hyperplasia and thiopurines: The case for level-dependent toxicity. Liver Transplantation, 2005, 11, 1300-1301.	2.4	41
32	Difficulties and possibilities with thiopurine therapy in inflammatory bowel diseaseâ€"Proceedings of the first Thiopurine Task Force meeting. Digestive and Liver Disease, 2011, 43, 270-276.	0.9	41
33	Detection of Sepsis in Preterm Infants by Fecal Volatile Organic Compounds Analysis. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, e47-e52.	1.8	41
34	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. Trials, 2015, 16, 366.	1.6	40
35	The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease. Inflammatory Bowel Diseases, 2016, 22, 2112-2120.	1.9	38
36	Sustained Clinical Benefit and Tolerability of Methotrexate Monotherapy After Thiopurine Therapy in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 667-672.	4.4	36

#	Article	IF	CITATIONS
37	Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study. Journal of Crohn's and Colitis, 2014, , .	1.3	36
38	Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 307-315.	1.3	36
39	6-Thioguanine for Crohn's disease during pregnancy: Thiopurine metabolite measurements in both mother and child. Scandinavian Journal of Gastroenterology, 2005, 40, 1374-1377.	1.5	35
40	Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. Journal of Crohn's and Colitis, 2012, 6, 95-101.	1.3	35
41	High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study. Inflammatory Bowel Diseases, 2021, 27, 352-363.	1.9	35
42	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. BMJ Open, 2017, 7, e016695.	1.9	33
43	Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease. Journal of Breath Research, 2018, 12, 016006.	3.0	32
44	Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Digestive and Liver Disease, 2011, 43, 110-115.	0.9	31
45	Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy. Molecular Diagnosis and Therapy, 2016, 20, 551-557.	3.8	31
46	Fecal Amino Acid Analysis Can Discriminate <i>De Novo</i> Treatmentâ€NaÃve Pediatric Inflammatory Bowel Disease From Controls. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 773-778.	1.8	30
47	Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Alimentary Pharmacology and Therapeutics, 2019, 50, 54-65.	3.7	30
48	IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. Inflammatory Bowel Diseases, 2020, 26, 167-180.	1.9	29
49	Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry. Analytical Chemistry, 2018, 90, 7972-7981.	6.5	28
50	Systematic review with metaâ€analysis: risk factors for thiopurineâ€induced leukopenia in IBD. Alimentary Pharmacology and Therapeutics, 2019, 50, 484-506.	3.7	28
51	Effects of Sampling Conditions and Environmental Factors on Fecal Volatile Organic Compound Analysis by an Electronic Nose Device. Sensors, 2016, 16, 1967.	3.8	27
52	Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study. Therapeutic Drug Monitoring, 2017, 39, 399-405.	2.0	27
53	Development of severe bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds. Pediatric Research, 2018, 83, 412-419.	2.3	27
54	Late-onset Sepsis in Preterm Infants Can Be Detected Preclinically by Fecal Volatile Organic Compound Analysis: A Prospective, Multicenter Cohort Study. Clinical Infectious Diseases, 2019, 68, 70-77.	5.8	27

#	Article	IF	Citations
55	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. Gastroenterology, 2019, 156, 11-14.	1.3	27
56	Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2015, 37, 797-804.	2.0	26
57	Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2016, 38, 621-627.	2.0	26
58	Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts. Inflammatory Bowel Diseases, 2017, 23, 2011-2017.	1.9	25
59	Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?. Journal of Cancer Research and Clinical Oncology, 2019, 145, 223-234.	2.5	25
60	Vedolizumab for Inflammatory Bowel Disease: Twoâ€Year Results of theÂlnitiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. Clinical Pharmacology and Therapeutics, 2020, 107, 1189-1199.	4.7	24
61	Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20â€year cohort study in all Dutch liver transplant units. United European Gastroenterology Journal, 2017, 5, 658-667.	3.8	23
62	6â€methylmercaptopurineâ€induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1183-1190.	2.8	23
63	The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review. Inflammatory Bowel Diseases, 2021, 27, 711-724.	1.9	23
64	Golimumab for the treatment of ulcerative colitis. Clinical and Experimental Gastroenterology, 2014, 7, 53.	2.3	22
65	Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 541-548.	1.3	22
66	Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 1920-1930.	1.3	22
67	Allopurinol Enhances the Activity of Hypoxanthine-Guanine Phosphoribosyltransferase in Inflammatory Bowel Disease Patients During Low-Dose Thiopurine Therapy: Preliminary Data of an Ongoing Series. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1085-1090.	1.1	21
68	Clinical experience and diagnostic algorithm of vulval Crohn's disease. European Journal of Gastroenterology and Hepatology, 2017, 29, 838-843.	1.6	21
69	Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. Alimentary Pharmacology and Therapeutics, 2018, 48, 761-767.	3.7	21
70	The continuous rediscovery and the benefit–risk ratio of thioguanine, a comprehensive review. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1-13.	3.3	21
71	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. Annals of Surgery, 2021, 273, 557-563.	4.2	21
72	Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications. Inflammatory Bowel Diseases, 2018, 24, 510-531.	1.9	20

#	Article	IF	CITATIONS
73	Salivary Function and Oral Health Problems in Crohn's Disease Patients. Inflammatory Bowel Diseases, 2018, 24, 1361-1367.	1.9	20
74	Realâ€life study of safety of thiopurineâ€allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. Alimentary Pharmacology and Therapeutics, 2019, 50, 407-415.	3.7	20
75	Profound Pathogen-Specific Alterations in Intestinal Microbiota Composition Precede Late-Onset Sepsis in Preterm Infants: A Longitudinal, Multicenter, Case-Control Study. Clinical Infectious Diseases, 2021, 73, e224-e232.	<b>5.</b> 8	20
76	6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: Dose or level dependent?. Journal of Hepatology, 2006, 44, 821-822.	3.7	19
77	Paradoxical Elevated Thiopurine S-Methyltransferase Activity After Pancytopenia During Azathioprine Therapy: Potential Influence of Red Blood Cell Age. Therapeutic Drug Monitoring, 2008, 30, 390-393.	2.0	19
78	Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2017, 39, 584-588.	2.0	19
79	Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study. Inflammatory Bowel Diseases, 2018, 24, 2468-2475.	1.9	19
80	Sniffing Out Paediatric Gastrointestinal Diseases. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 585-591.	1.8	18
81	Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol–Thiopurine Combination Therapy. Inflammatory Bowel Diseases, 2017, 23, 448-452.	1.9	18
82	A comparative analysis of tioguanine versus lowâ€dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2020, 51, 1076-1086.	3.7	18
83	Dental and periodontal disease in patients with inflammatory bowel disease. Clinical Oral Investigations, 2021, 25, 5273-5280.	3.0	18
84	The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose. Journal of Breath Research, 2019, 13, 046001.	3.0	17
85	Morphological spectrum of neovaginitis in autologous sigmoid transplant patients. Histopathology, 2016, 68, 1004-1012.	2.9	16
86	Faecal Scent as a Novel Non-Invasive Biomarker to Discriminate between Coeliac Disease and Refractory Coeliac Disease: A Proof of Principle Study. Biosensors, 2019, 9, 69.	4.7	16
87	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology, 2019, 54, 700-706.	1.5	16
88	Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?. Journal of Crohn's and Colitis, 2020, 14, 1299-1315.	1.3	16
89	The associations of thiopurines with male fertility and paternally exposed offspring: a systematic review and meta-analysis. Human Reproduction Update, 2018, 24, 192-206.	10.8	15
90	Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. Clinical Gastroenterology and Hepatology, 2019, 17, 568-570.	4.4	15

#	Article	IF	CITATIONS
91	Predictive factors for surgical treatment in preterm neonates with necrotizing enterocolitis: a multicenter case-control study. European Journal of Pediatrics, 2021, 180, 617-625.	2.7	15
92	Ipilimumab in a patient with known Crohn's disease: To give or not to give?. Journal of Crohn's and Colitis, 2014, 8, 1742.	1.3	14
93	Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial. Journal of Crohn's and Colitis, 2021, 15, 1106-1113.	1.3	14
94	Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2022, 67, 4008-4019.	2.3	14
95	Fecal Amino Acid Analysis in Newly Diagnosed Pediatric Inflammatory Bowel Disease: A Multicenter Case-Control Study. Inflammatory Bowel Diseases, 2022, 28, 755-763.	1.9	14
96	Stability of Thiopurine Metabolites: A Potential Analytical Bias. Clinical Chemistry, 2008, 54, 216-218.	3.2	13
97	Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. BMC Gastroenterology, 2011, 11, 47.	2.0	13
98	Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 159-165.	1.3	13
99	Fecal Volatile Organic Compounds in Preterm Infants Are Influenced by Enteral Feeding Composition. Sensors, 2018, 18, 3037.	3.8	13
100	The teratogenicity of allopurinol: A comprehensive review of animal and human studies. Reproductive Toxicology, 2018, 81, 180-187.	2.9	13
101	Leukopenia due to <i>Parvovirus B19</i> in a Crohn's Disease Patient Using Azathioprine. Digestion, 2009, 79, 211-214.	2.3	12
102	Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflammatory Bowel Diseases, 2018, 24, 67-77.	1.9	12
103	Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 637-645.	0.9	12
104	Application of Fecal Volatile Organic Compound Analysis in Clinical Practice: Current State and Future Perspectives. Chemosensors, 2018, 6, 29.	3.6	11
105	Effect of Daily Intake of Lactobacillus casei on Microbial Diversity and Dynamics in a Healthy Pediatric Population. Current Microbiology, 2019, 76, 1020-1027.	2.2	11
106	Key insights from therapeutic drug monitoring in Crohn's disease patients. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 399-406.	3.3	11
107	The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma. Gut Microbes, 2022, 14, 2038863.	9.8	11
108	Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient. Inflammatory Bowel Diseases, 2011, 17, E26.	1.9	10

#	Article	IF	CITATIONS
109	Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2016, 38, 463-470.	2.0	10
110	Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2016, 28, 991-996.	1.6	10
111	Simultaneous Assessment of Urinary and Fecal Volatile Organic Compound Analysis in De Novo Pediatric IBD. Sensors, 2019, 19, 4496.	3.8	10
112	Optimized sample preparation for fecal volatile organic compound analysis by gas chromatography–mass spectrometry. Metabolomics, 2020, 16, 112.	3.0	10
113	Animal Olfactory Detection of Disease: Promises and Pitfalls. Clinical Chemistry, 2014, 60, 1473-1479.	3.2	9
114	High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients. Nucleosides, Nucleotides and Nucleic Acids, 2018, 37, 317-323.	1.1	9
115	Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology, 2019, 54, 753-760.	1.5	9
116	Oral health and salivary function in ulcerative colitis patients. United European Gastroenterology Journal, 2020, 8, 1067-1075.	3.8	9
117	The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis. Digestive and Liver Disease, 2020, 52, 745-752.	0.9	9
118	An Overview of Robotic Capsules for Drug Delivery to the Gastrointestinal Tract. Journal of Clinical Medicine, 2021, 10, 5791.	2.4	9
119	Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction. Digestive Diseases and Sciences, 2012, 57, 250-253.	2.3	8
120	Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Digestive and Liver Disease, 2018, 50, 48-53.	0.9	8
121	Fecal Volatile Organic Compound Profiles are Not Influenced by Gestational Age and Mode of Delivery: A Longitudinal Multicenter Cohort Study. Biosensors, 2020, 10, 50.	4.7	8
122	Spot diagnosis: Eruptive melanocytic naevi during azathioprine therapy in Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 636.	1.3	7
123	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Inflammatory Bowel Diseases, 2018, 24, 1558-1565.	1.9	7
124	The influence of timing of Maternal administration of Antibiotics during cesarean section on the intestinal Microbial colonization in Infants (MAMI-trial): study protocol for a randomised controlled trial. Trials, 2019, 20, 479.	1.6	7
125	The effect of surgical fecal stream diversion of the healthy colon on the colonic microbiota. European Journal of Gastroenterology and Hepatology, 2019, 31, 451-457.	1.6	7
126	Validation of the inflammatory bowel disease disability index for selfâ€report and development of an itemâ€reduced version. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 92-102.	2.8	7

#	Article	IF	CITATIONS
127	Drug Rediscovery to Prevent O-Label Prescription Reduces Health Care Costs: the Case of Tioguanine in e Netherlands. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 123-125.	0.9	7
128	The Thiopurine Tale: An Unexpected Journey. Journal of Crohn's and Colitis, 2022, 16, 1177-1183.	1.3	7
129	Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 669-671.	3.0	6
130	Neovaginal Sparing in a Transgender Woman With UlcerativeÂColitis. Clinical Gastroenterology and Hepatology, 2016, 14, e73-e74.	4.4	6
131	Altered Tryptophan Levels in Patients With Inflammatory Bowel Disease Owing to Colonic Leakage, Metabolism, or Malabsorption?. Gastroenterology, 2018, 154, 1855-1856.	1.3	6
132	Smoking Influences Fecal Volatile Organic Compounds Composition. Clinical Gastroenterology and Hepatology, 2018, 16, 1168-1169.	4.4	6
133	Non-Invasive Detection of Anastomotic Leakage Following Esophageal and Pancreatic Surgery by Urinary Analysis. Digestive Surgery, 2019, 36, 173-180.	1.2	6
134	Offâ€label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1293-1300.	3.7	6
135	Successful Treatment of Oral Crohn's Disease by Ustekinumab. Inflammatory Bowel Diseases, 2020, 26, e19-e19.	1.9	6
136	Smell—Adding a New Dimension to Urinalysis. Biosensors, 2020, 10, 48.	4.7	6
137	Overcoming Workplace Disability in IBD Patients: An Observational Study. Inflammatory Intestinal Diseases, 2020, 5, 84-92.	1.9	6
138	Preclinical Detection of Non-catheter Related Late-onset Sepsis in Preterm Infants by Fecal Volatile Compounds Analysis. Pediatric Infectious Disease Journal, 2020, 39, 330-335.	2.0	6
139	Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 91-97.	1.3	6
140	Systematic review: nonâ€endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome. Alimentary Pharmacology and Therapeutics, 2022, 55, 778-788.	3.7	6
141	Management of Crohn's disease in poor responders to adalimumab. Clinical and Experimental Gastroenterology, 2014, 7, 83.	2.3	5
142	Mesalazine and Nephrolithiasis: Leave No Stone Unturned. American Journal of Gastroenterology, 2019, 114, 1359-1360.	0.4	5
143	Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2020, 51, 1353-1364.	3.7	5
144	Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. Digestive Diseases and Sciences, 2021, , .	2.3	5

#	Article	IF	CITATIONS
145	Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis, 2022, 16, 1777-1790.	1.3	5
146	On the malignant potential of thiopurine therapy. Blood, 2009, 113, 6258-6258.	1.4	4
147	Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol–thiopurine cotherapy. European Journal of Gastroenterology and Hepatology, 2018, 30, 1254-1255.	1.6	4
148	Orofacial Granulomatosis Associated with Crohn's Disease: a Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 430-435.	1.3	4
149	Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent. Sensors, 2022, 22, 2316.	3.8	4
150	Vulvar and vaginal neoplasia in women with inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 149-155.	0.9	3
151	The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Diseaseâ€"A Systematic Literature Review. Pharmaceutics, 2022, 14, 1241.	4.5	3
152	Beneficial pharmacological interaction between thiopurine and mesalazine â€" Never change a winning team. Journal of Crohn's and Colitis, 2014, 8, 1743-1744.	1.3	2
153	Get the Best Out of Thiopurine Therapy. Gastroenterology, 2014, 146, 865.	1.3	2
154	Proximal esophageal cancer missed during esophagogastroduodenoscopy: should the detection of an inlet patch be added to the quality criteria for upper gastrointestinal endoscopy?. Endoscopy, 2016, 48, E273-E273.	1.8	2
155	Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. Inflammatory Bowel Diseases, 2022, 28, S16-S24.	1.9	2
156	Low and adequately dosed 6-thioguanine: Not so bad after all. Inflammatory Bowel Diseases, 2008, 14, 1166-1167.	1.9	1
157	ECCO consensus: Evidence-based use of 6-thioguanine therapy in Crohn's disease?. Journal of Crohn's and Colitis, 2010, 4, 484-485.	1.3	1
158	Oxidation-Mediated DNA Crosslinking Contributes to Toxicity of 6-Thioguanine in Human Cells â€" Letter. Cancer Research, 2013, 73, 1445-1445.	0.9	1
159	Optimize Thiopurine Therapy in Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1062-1063.	4.4	1
160	Accelerating with the brakes on?. International Journal of Antimicrobial Agents, 2017, 50, 738.	2.5	1
161	Revival of an ancient Greek art: scent detection as diagnostic tool for tuberculosis. Pediatric Research, 2018, 84, 4-5.	2.3	1
162	Pseudomyxoma peritonei of the appendix after ileocecal resection: Expect the unexpected. Digestive and Liver Disease, 2019, 51, 1486.	0.9	1

#	Article	IF	CITATIONS
163	Let Us Not Forget HPV Vaccination in Women and Men in IBD. Inflammatory Bowel Diseases, 2019, 25, e11-e11.	1.9	1
164	Discontinuation rate of azathioprine. Liver International, 2020, 40, 3141-3141.	3.9	1
165	Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound. Inflammatory Bowel Diseases, 2021, 27, e114-e115.	1.9	1
166	Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy. Journal of Crohn's and Colitis, 2021, 15, 1244-1245.	1.3	1
167	Patient-Reported Experiences with a Relicensed Generic: Thioguanine for the Treatment of Inflammatory Bowel Diseases. Journal of Gastrointestinal and Liver Diseases, 2018, 27, 385-389.	0.9	1
168	An Immovable Nasojejunal Feeding Tube. Clinical Gastroenterology and Hepatology, 2010, 8, A24.	4.4	0
169	Duodenal lymphoid nodularity in common variable immunodeficiency. Digestive and Liver Disease, 2013, 45, e5.	0.9	0
170	Reply. Clinical Gastroenterology and Hepatology, 2013, 11, 1039.	4.4	0
171	Allopurinol in Subjects with Colorectal Adenoma—Letter. Cancer Prevention Research, 2013, 6, 368-368.	1.5	0
172	Neovaginal diverticula: pathophysiology of colonic diverticulosis revisited. Endoscopy, 2015, 47, E611-E611.	1.8	0
173	A plea for TDM-based optimisation for treatment of Crohn's disease. The Lancet Gastroenterology and Hepatology, 2017, 2, 81.	8.1	0
174	Do not forget to culture. Digestive and Liver Disease, 2017, 49, 1060.	0.9	0
175	Paternal use of thiopurines and methotrexate: Are we reassured enough?. Reproductive Toxicology, 2018, 75, 146.	2.9	0
176	All Thiopurines Are Equal but Some Thiopurines Are More Equal Than Others. JAMA Oncology, 2018, 4, 420.	7.1	0
177	Letter: off″abel use of hyperbaric oxygen therapy in inflammatory bowel disease—Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 216-217.	3.7	0
178	Cutaneous Metastasis From a Laryngeal Carcinoma After Push Method Percutaneous Endoscopic Gastrostomy. American Journal of Gastroenterology, 2021, 116, 235-235.	0.4	0
179	The Launch of an Online National Multidisciplinary Expert Panel for Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, , .	1.3	0
180	Knowledge and Interdisciplinary Communication of Gastroenterologists and Dentists in the Netherlands About Gastrointestinal Diseases With Oral Manifestations. Crohn's & Colitis 360, 2022, 4, .	1.1	0

11